Tijana Stankovic

Tijana Stankovic

Auto-generated profile, based on publicly available information

Tijana Stankovic

Institute for Biological Research, Department of Neurobiology, University of Belgrade, Bulevar Despota Stefana 142, Belgrade, Serbia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2019 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
TSTijana Stanković
Tijana Stanković
JDJelena Dinić
Jelena Dinić
Ana Podolski-RenićAna Podolski-Renić
Ana Podolski-Renić
LMLoana Musso
Loana Musso
SBSonja Stojković Burić
Sonja Stojković Burić
Milica PešićMilica Pešić
Milica Pešić
Background: Dual-targeting in cancer treatment by a single drug is an unconventional approach in relation to drug combinations. The rationale for the development of dualtargeting agents is to overcome incomplete efficacy and drug resistance frequently present when applying individual targeting agents. Consequently, -a more favorable outcome of cancer treatment is expected with dual-targeting strategies.Methods: We reviewed the literature, concentrating on the association between clinically relevant and/or novel dual inhibitors with the potential to modulate multidrug resistant phenotype of cancer cells, particularly the activity of P-glycoprotein. A balanced analysis of content was performed to emphasize the most important findings and optimize the structure of this review.Results: Two-hundred and forty-five papers were included in the review. The introductory part was interpreted by 9 papers. Tyrosine kinase inhibitors’ role in the inhibition of Pglycoprotein and chemosensitization was illustrated by 87 papers. The contribution of naturalbased compounds in overcoming multidrug resistance was reviewed using 92 papers, while specific dual inhibitors acting against microtubule assembling and/or topoisomerases were described with 55 papers. Eleven papers gave an insight into a novel and less explored approach with hybrid drugs. Their influence on P-glycoprotein and multidrug resistance was also evaluated.Conclusion: These findings bring into focus rational anticancer strategies with dual-targeting agents. Most evaluated synthetic and natural drugs showed a great potential in chemosensitization. Further steps in this direction are needed for the optimization of anticancer treatment.

16 December 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
VMVedrana Milinkovic
Vedrana Milinkovic
JBJasna Bankovic
Jasna Bankovic
MRMiodrag Rakic
Miodrag Rakic
TSTijana Stankovic
Tijana Stankovic
MSMilica Skender-Gazibara
Milica Skender-Gazibara
NTNikola Tanic
Nikola Tanic
Glioblastoma is the most frequent and malignant human brain tumor. High level of genomic instability detected in glioma cells implies that numerous genetic alterations accumulate during glioma pathogenesis. We investigated alterations in AP-PCR DNA profiles of 30 glioma patients, and detected specific changes in 11 genes not previously associated with this disease: LHFPL3, SGCG, HTR4, ITGB1, CPS1, PROS1, GP2, KCNG2, PDE4D, KIR3DL3, and INPP5A. Further correlations revealed that 8 genes might play important role in pathogenesis of glial tumors, while changes in GP2, KCNG2 and KIR3DL3 should be considered as passenger mutations, consequence of high level of genomic instability. Identified genes have a significant role in signal transduction or cell adhesion, which are important processes for cancer development and progression. According to our results, LHFPL3 might be characteristic of primary glioblastoma, SGCG, HTR4, ITGB1, CPS1, PROS1 and INPP5A were detected predominantly in anaplastic astrocytoma, suggesting their role in progression of secondary glioblastoma, while alterations of PDE4D seem to have important role in development of both glioblastoma subtypes. Some of the identified genes showed significant association with p53, p16, and EGFR, but there was no significant correlation between loss of PTEN and any of identified genes. In conclusion our study revealed genetic alterations that were not previously associated with glioma pathogenesis and could be potentially used as molecular markers of different glioblastoma subtypes.

1 November 2014 in Translational Research
Verified
Journal Article
Closed access
ZMZorica Milosevic
Zorica Milosevic
Milica PešićMilica Pešić
Milica Pešić
TSTijana Stankovic
Tijana Stankovic
JDJelena Dinić
Jelena Dinić
ZMZorka Milovanovic
Zorka Milovanovic
JBJasna Bankovic
Jasna Bankovic

7 November 2016 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
MDMiodrag Dragoj
Miodrag Dragoj
ZMZorica Milosevic
Zorica Milosevic
JBJasna Bankovic
Jasna Bankovic
NTNikola Tanic
Nikola Tanic
Milica PešićMilica Pešić
Milica Pešić
TSTijana Stankovic
Tijana Stankovic

19 June 2019 in Cancers
Verified
Journal Article
Open access
PDF file
AFAnna Lucia Fallacara
Anna Lucia Fallacara
CZclaudio zamperini
claudio zamperini
Ana Podolski-RenićAna Podolski-Renić
Ana Podolski-Renić
JDJelena Dinić
Jelena Dinić
TSTijana Stanković
Tijana Stanković
Silvia SchenoneSilvia Schenone
Silvia Schenone
Overexpression of P-glycoprotein (P-gp) and other ATP-binding cassette (ABC) transporters in multidrug resistant (MDR) cancer cells is responsible for the reduction of intracellular drug accumulation, thus decreasing the efficacy of chemotherapeutics. P-gp is also found at endothelial cells’ membrane of the blood-brain barrier, where it limits drug delivery to central nervous system (CNS) tumors. We have previously developed a set of pyrazolo[3,4-d]pyrimidines and their prodrugs as novel Src tyrosine kinase inhibitors (TKIs), showing a significant activity against CNS tumors in in vivo. Here we investigated the interaction of the most promising pair of drug/prodrug with P-gp at the cellular level. The tested compounds were found to increase the intracellular accumulation of Rho 123, and to enhance the efficacy of paclitaxel in P-gp overexpressing cells. Encouraging pharmacokinetics properties and tolerability in vivo were also observed. Our findings revealed a novel role of pyrazolo[3,4-d]pyrimidines which may be useful for developing a new effective therapy in MDR cancer treatment, particularly against glioblastoma.

12 November 2015 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
JDJelena Dinić
Jelena Dinić
Ana Podolski-RenićAna Podolski-Renić
Ana Podolski-Renić
TSTijana Stankovic
Tijana Stankovic
JBJasna Bankovic
Jasna Bankovic
Milica PešićMilica Pešić
Milica Pešić
Resistance to chemotherapeautic drugs is one of the main obstacles to effective cancer treatment. Multidrug resistance (MDR) is defined as resistance to structurally and/or functionally unrelated drugs, and has been extensively investigated for the last three decades. There are two types of MDR: intrinsic and acquired. Tumor microenvironment selection pressure leads to the development of intrinsic MDR, while acquired resistance is a consequence of the administered chemotherapy. A central issue in chemotherapy failure is the existence of heterogeneous populations of cancer cells within one patient and patient-to-patient variability within each type of cancer. Numerous genes and pathways contribute to the development of MDR in cancer. Point mutations, gene amplification or other genetic or epigenetic changes all affect biological functions and may lead to the occurrence of MDR phenotype. Similar to the characteristics of cancerogenesis, the main features of MDR include abnormal tumor vasculature, regions of hypoxia, aerobic glycolysis, and a lower susceptibility to apoptosis. In order to achieve a lethal effect on cancer cells, drugs need to reach their intracellular target molecules. The overexpression of the efflux transporter P-glycoprotein (P-gp) in MDR cancer cells leads to decreased uptake of the drug and intracellular drug accumulation, minimising drug-target interactions. New agents being or inspired by natural products that sucessfully target these mechanisms are the main subject of this review. Two key approaches in combating MDR in cancer are discussed (i) finding agents that preserve citotoxicity toward MDR cancer cells; (ii) developing compounds that restore the cytotoxic activity of classic anticancer drugs.